-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: Nasdaq Biotech Index
Nasdaq Biotech Index re-ranking for next Monday
Twice a year, in May and November, the NASDAQ OMX Group re-ranks the closely watched Nasdaq Biotechnology Index (NBI). This Monday (May 23rd), six companies will be added to the Nasdaq Biotech index and two will be removed. The additions are Achillion Pharmaceuticals (ACHN), AVEO Pharmaceuticals (AVEO), Columbia Laboratories (CBRX), ISTA Pharmaceuticals (ISTA), Pacific Biosciences (PACB) and Zalicus (ZLCS). The two companies to be removed from the NBI are Biodel (BIOD) and China Sky One Read More >
Biotech Sector Performance Update 1H 2010
In my last update back in April, the broadest Biotech index (the 125 company Nasdaq Biotech Index, NBI) was up 11% for the year and ahead of just about every major sector. One quarter later things look a little different. The NBI is now down 5% and trailing 4 of the 10 S&P sectors (chart 1): However, the spotlight continues to shine on the AMEX Biotech Index (BTK). The BTK is up 8.6% for the Read More >
